GBrain MRI
by Galileo Cds, Inc. 510(k)
Active
510(k) K252362
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK252362 | Date22 Aug 2025 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 22 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- QIH
- Device Class
- Class II
- Regulation
- 21 CFR Part 892.2050
- Advisory Committee
- Radiology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
GBrain MRI is an AI-enabled medical device for automated segmentation, quantification, and reporting of signal hyperintensities in brain MRI. It is pathology agnostic and does not require a prior diagnosis for use.
GBrain MRI received FDA 510(k) clearance (K252362) on 2025-08-22, with a special clearance type and review by the Radiology advisory committee. It is manufactured by Galileo Cds, Inc. in Austin, Texas, and is intended for use in radiology settings to process MRI images.
Other devices from Galileo Cds, Inc.
Questions
AI-generated answers, 1 Oct 2026
What is GBrain MRI used for?
GBrain MRI is used for automated segmentation, quantification, and reporting of signal hyperintensities in brain MRI images. It is pathology agnostic, meaning it does not require a prior diagnosis to operate, allowing radiologists to process scans for analysis regardless of suspected condition.
How is GBrain MRI supplied or accessed?
GBrain MRI is a software-based medical device intended for use in radiology settings to process MRI images. It is manufactured by Galileo Cds, Inc. in Austin, Texas, and is accessed as a digital tool integrated into radiology workflows, not as a physical product shipped in units.
Does GBrain MRI require a prior diagnosis to function?
No, GBrain MRI does not require a prior diagnosis for use. The device is explicitly described as pathology agnostic, meaning it can analyze brain MRI scans for signal hyperintensities without needing a pre-existing clinical diagnosis, enabling broad application in radiological assessment.